...
首页> 外文期刊>Therapeutics and Clinical Risk Management >Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
【24h】

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes

机译:2型糖尿病患者心血管风险管理的进展:来自2型糖尿病心血管风险,结果和安全性研究学院的观点

获取原文
           

摘要

Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies. In 2015, EMPA-REG OUTCOME? became the first CVOT to present results for a sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitor, empagliflozin. Subsequently, a regional meeting of the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) brought together a respected faculty of international experts and 150 physicians from 14 countries to discuss the current unmet medical needs of patients with T2D, the results from the EMPA-REG OUTCOME study and the implications of these results for clinical practice. This article summarizes the current scientific evidence and the discussions that took place at the ACROSS T2D regional meeting, which was held in Vienna, Austria, on May 30, 2016.
机译:糖尿病是一项全球性的突发卫生事件,预计到2040年将影响6.42亿人。2型糖尿病(T2D)代表90%的糖尿病病例,并且与一系列心血管(CV)危险因素相关,是CV疾病发病率的两倍以上并显着提高死亡率。糖尿病治疗通常集中在改善血糖控制上,但它们对心血管结果的影响仍不确定。 2008年,美国食品药品监督管理局(FDA)试图解决这一知识差距,并要求对所有新的抗糖尿病疗法进行CV结果试验(CVOT)。 2015年,EMPA-REG OUTCOME ?成为首个展示钠/葡萄糖共转运蛋白2(SGLT2;也称为SLC5A2)抑制剂依帕列净的结果的CVOT。随后,在2型糖尿病心血管风险,结果和安全性研究学院(ACROSS T2D)的一次区域会议上,由来自14个国家/地区的国际专家和150位医师组成了受人尊敬的教师队伍,讨论了T2D患者当前未满足的医疗需求, EMPA-REG OUTCOME研究的结果以及这些结果对临床实践的意义。本文总结了当前的科学证据以及2016年5月30日在奥地利维也纳举行的ACROSS T2D区域会议上进行的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号